Neuren Pharmaceuticals Partner Acadia Reports Record Q2 Daybue Sales; Shares Up 17%

MT Newswires Live08-05

Neuren Pharmaceuticals (ASX:NEU) reported a strong second-quarter update from partner Acadia Pharmaceuticals, with Daybue sales reaching a record $125 million, marking a 30% year-on-year increase and a 24% rise from the previous quarter, according to a Wednesday filing with the Australian bourse.

Acadia increased its 2026 Daybue sales guidance to $480 million to $510 million, supported by strong US adoption of the new STIX formulation, with 40% of patients transitioning by the end of the quarter, per the filing.

The company highlighted its global expansion progress, including a positive opinion from the Committee for Medicinal Products for Human Use supporting European approval and plans for a potential German launch in the fourth quarter.

The company reported $12.9 million in the second quarter royalty earnings and raised its 2026 royalty guidance to $53 million to $56 million, the filing added.

The company's shares jumped 17% in recent Wednesday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2657962715?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 09:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2657962715","market":"sg","top_or_hot":-1,"title":"Neuren Pharmaceuticals Partner Acadia Reports Record Q2 Daybue Sales; Shares Up 17%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/NEU.AU\">Neuren Pharmaceuticals</a> (ASX:NEU) reported a strong second-quarter update from partner Acadia Pharmaceuticals, with Daybue sales reaching a record $125 million, marking a 30% year-on-year increase and a 24% rise from the previous quarter, according to a Wednesday filing with the Australian bourse.</p><p>Acadia increased its 2026 Daybue sales guidance to $480 million to $510 million, supported by strong US adoption of the new STIX formulation, with 40% of patients transitioning by the end of the quarter, per the filing.</p><p>The company highlighted its global expansion progress, including a positive opinion from the Committee for Medicinal Products for Human Use supporting European approval and plans for a potential German launch in the fourth quarter.</p><p>The company reported $12.9 million in the second quarter royalty earnings and raised its 2026 royalty guidance to $53 million to $56 million, the filing added.</p><p>The company's shares jumped 17% in recent Wednesday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neuren Pharmaceuticals Partner Acadia Reports Record Q2 Daybue Sales; Shares Up 17%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuren Pharmaceuticals Partner Acadia Reports Record Q2 Daybue Sales; Shares Up 17%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-05 09:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/NEU.AU\">Neuren Pharmaceuticals</a> (ASX:NEU) reported a strong second-quarter update from partner Acadia Pharmaceuticals, with Daybue sales reaching a record $125 million, marking a 30% year-on-year increase and a 24% rise from the previous quarter, according to a Wednesday filing with the Australian bourse.</p><p>Acadia increased its 2026 Daybue sales guidance to $480 million to $510 million, supported by strong US adoption of the new STIX formulation, with 40% of patients transitioning by the end of the quarter, per the filing.</p><p>The company highlighted its global expansion progress, including a positive opinion from the Committee for Medicinal Products for Human Use supporting European approval and plans for a potential German launch in the fourth quarter.</p><p>The company reported $12.9 million in the second quarter royalty earnings and raised its 2026 royalty guidance to $53 million to $56 million, the filing added.</p><p>The company's shares jumped 17% in recent Wednesday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AKR","symbol_name":"阿卡迪亚房地产信托","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2657962715","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2657962715","pubTimestamp":1785893034,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Neuren Pharmaceuticals  reported a strong second-quarter update from partner Acadia Pharmaceuticals, with Daybue sales reaching a record $125 million, marking a 30% year-on-year increase and a 24% rise from the previous quarter, according to a Wednesday filing with the Australian bourse.Acadia increased its 2026 Daybue sales guidance to $480 million to $510 million, supported by strong US adoption of the new STIX formulation, with 40% of patients transitioning by the end of the quarter, per the filing.The company highlighted its global expansion progress, including a positive opinion from the Committee for Medicinal Products for Human Use supporting European approval and plans for a potential German launch in the fourth quarter.The company reported $12.9 million in the second quarter royalty earnings and raised its 2026 royalty guidance to $53 million to $56 million, the filing added.The company's shares jumped 17% in recent Wednesday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"AKR":"阿卡迪亚房地产信托"},"translate_title":"Neuren Pharmaceuticals 合作伙伴 Acadia 报告第二季度 Daybue 销售额创历史新高；股价上涨 17%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKR":1.5},"content_text":"Neuren Pharmaceuticals (ASX:NEU) reported a strong second-quarter update from partner Acadia Pharmaceuticals, with Daybue sales reaching a record $125 million, marking a 30% year-on-year increase and a 24% rise from the previous quarter, according to a Wednesday filing with the Australian bourse.Acadia increased its 2026 Daybue sales guidance to $480 million to $510 million, supported by strong US adoption of the new STIX formulation, with 40% of patients transitioning by the end of the quarter, per the filing.The company highlighted its global expansion progress, including a positive opinion from the Committee for Medicinal Products for Human Use supporting European approval and plans for a potential German launch in the fourth quarter.The company reported $12.9 million in the second quarter royalty earnings and raised its 2026 royalty guidance to $53 million to $56 million, the filing added.The company's shares jumped 17% in recent Wednesday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2657962715","isCrawlerRequest":true}